Literature DB >> 25468274

DA virus mutant H101 has altered CNS pathogenesis and causes immunosuppression.

Matthew F Cusick1, Jane E Libbey1, Daniel J Doty1, Robert S Fujinami2.   

Abstract

Viruses use various mechanisms to evade clearance by the host. Investigating how a few changes in the genome of a non-lethal virus can lead to altered disease, from survivable to immunosuppression/death, would provide valuable information into viral pathogenesis. The Daniels strain of Theiler's murine encephalomyelitis virus causes an asymptomatic infection or acute encephalitis followed by viral clearance. A mutant, H101, carries several alterations in the viral genome. H101 infection causes profound immunosuppression and death. Thus, a virus that is normally cleared by its natural host can become lethal due to just a few changes in the viral genome.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Immunosuppression; Picornavirus; T cell; Viral pathogenesis

Mesh:

Substances:

Year:  2014        PMID: 25468274      PMCID: PMC4314319          DOI: 10.1016/j.jneuroim.2014.10.012

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  29 in total

1.  Natural interspecies recombinant bovine/porcine enterovirus in sheep.

Authors:  Ákos Boros; Péter Pankovics; Nick J Knowles; Gábor Reuter
Journal:  J Gen Virol       Date:  2012-05-30       Impact factor: 3.891

2.  Innate but not adaptive immune responses contribute to behavioral seizures following viral infection.

Authors:  Nikki J Kirkman; Jane E Libbey; Karen S Wilcox; H Steve White; Robert S Fujinami
Journal:  Epilepsia       Date:  2009-10-20       Impact factor: 5.864

3.  Theiler's virus and Mengo virus induce cross-reactive cytotoxic T lymphocytes restricted to the same immunodominant VP2 epitope in C57BL/6 mice.

Authors:  S Dethlefs; N Escriou; M Brahic; S van der Werf; E L Larsson-Sciard
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Prolonged gray matter disease without demyelination caused by Theiler's murine encephalomyelitis virus with a mutation in VP2 puff B.

Authors:  I Tsunoda; Y Wada; J E Libbey; T S Cannon; F G Whitby; R S Fujinami
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 5.  Studies in the modulation of experimental autoimmune encephalomyelitis.

Authors:  Jane E Libbey; Ikuo Tsunoda; Robert S Fujinami
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-17       Impact factor: 4.147

6.  Immune regulation and evasion of Mammalian host cell immunity during viral infection.

Authors:  B M Pratheek; Soham Saha; Prasanta K Maiti; Soma Chattopadhyay; Subhasis Chattopadhyay
Journal:  Indian J Virol       Date:  2013-03-15

7.  Theiler's virus infection of beta 2-microglobulin-deficient mice.

Authors:  L Fiette; C Aubert; M Brahic; C P Rossi
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  B-lymphocyte requirement for vaccine-mediated protection from Theiler's murine encephalomyelitis virus-induced central nervous system disease.

Authors:  C I Kurtz; X M Sun; R S Fujinami
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

9.  Cardioviruses are genetically diverse and cause common enteric infections in South Asian children.

Authors:  Olga Blinkova; Amit Kapoor; Joseph Victoria; Morris Jones; Nathan Wolfe; Asif Naeem; Shahzad Shaukat; Salmaan Sharif; Muhammad Masroor Alam; Mehar Angez; Sohail Zaidi; Eric L Delwart
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

10.  Serious invasive Saffold virus infections in children, 2009.

Authors:  Alex Christian Yde Nielsen; Blenda Böttiger; Jytte Banner; Thomas Hoffmann; Lars Peter Nielsen
Journal:  Emerg Infect Dis       Date:  2012-01       Impact factor: 6.883

View more
  1 in total

1.  The role of peripheral interleukin-6 in the development of acute seizures following virus encephalitis.

Authors:  Matthew F Cusick; Jane E Libbey; Daniel J Doty; Ana Beatriz DePaula-Silva; Robert S Fujinami
Journal:  J Neurovirol       Date:  2017-07-24       Impact factor: 2.643

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.